Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published December 19, 2023 | v1
Journal Article Open

miRNA-211 maintains metabolic homeostasis in medulloblastoma through its target gene long-chain acyl-CoA synthetase 4

Abstract

The prognosis of childhood medulloblastoma (MB) is often poor, and it usually requires aggressive therapy that adversely affects quality of life. microRNA-211 (miR-211) was previously identified as an important regulator of cells that descend from neural cells. Since medulloblastomas primarily affect cells with similar ontogeny, we investigated the role and mechanism of miR-211 in MB. Here we showed that miR-211 expression was highly downregulated in cell lines, PDXs, and clinical samples of different MB subgroups (SHH, Group 3, and Group 4) compared to normal cerebellum. miR-211 gene was ectopically expressed in transgenic cells from MB subgroups, and they were subjected to molecular and phenotypic investigations. Monoclonal cells stably expressing miR-211 were injected into the mouse cerebellum. miR-211 forced expression acts as a tumor suppressor in MB both in vitro and in vivo, attenuating growth, promoting apoptosis, and inhibiting invasion. In support of emerging regulatory roles of metabolism in various forms of cancer, we identified the acyl-CoA synthetase long-chain family member (ACSL4) as a direct miR-211 target. Furthermore, lipid nanoparticle-coated, dendrimer-coated, and cerium oxide-coated miR-211 nanoparticles were applied to deliver synthetic miR-211 into MB cell lines and cellular responses were assayed. Synthesizing nanoparticle-miR-211 conjugates can suppress MB cell viability and invasion in vitro. Our findings reveal miR-211 as a tumor suppressor and a potential therapeutic agent in MB. This proof-of-concept paves the way for further pre-clinical and clinical development.

Copyright and License

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Funding

Schamroth Project funded by Ian's Friends Foundation to RJP and GJ. The Hough Foundation made a grant to RJP and GJ. This study was supported by P30 CA006973 (JHU SKCCC) to RJP, CGE, ER, and CB, NCI 5P30CA030199 (SBP) RW-R, R01NS124668-01A1 to RJP and CPRIT Scholar to MDT.

Contributions

Study design: MY, RJP, AR, BL, RP, KK. Experimental work: MY, HK, RP, KK, and IM. Provision of cell lines, patient samples, TMAs, FFPE sections, and PDXs for the study: CGE, ER, and RWR. Data analysis: IM, PC, RP, OS, KJ, IG. Nanoparticles and Chemistry: EK, SS, SA, JH, WL, and RK. Metabolomics and lipidomics: IM and TG. Wrote the main draft of text: MY, RJP, IM KK, IM, RZ, SS, GJ, ER, MDT, RWR, OS, AR and CGE. Revised and approved the final version of the manuscript: All authors.

Conflict of Interest

The authors declare no competing interest.

Files

40478_2023_Article_1684.pdf
Files (95.1 MB)
Name Size Download all
md5:f4738189b9268fd3246c1041daa3aea7
10.0 MB Preview Download
md5:0c9cbf3d99bdaadaa66a9686085f1d46
12.2 kB Download
md5:a3dd0e77fc9b8d6294885447b9e1ff2e
31.9 kB Download
md5:118f08786823ecc7af5ff141e9e77133
74.8 MB Download
md5:83d4e76ecffa47b161910de50ed34f58
53.5 kB Download
md5:5a3a305851e8c1edf8b8d2a06a4034c8
10.2 MB Download

Additional details

Created:
December 20, 2023
Modified:
December 20, 2023